Related Experiment Videos
[Development of human monoclonal antibodies. Current status and future development]
Abstract:
The "state of the art" in the development of human monoclonal antibodies is reported. The classical cellular fusion method according to well established procedures, the Epstein-Barr virus mediated B-lymphocyte transformation and the modern genetic engineering method to obtain chimeric antibodies is reviewed in detail. Although they were praised in the last five years as the most efficient drugs against cancer and infectious diseases, no great success was clinically and experimentally reported in the past. The many experimental obstacles hindered the efficient development of these promising drugs. In the last two years, however, new ways were proposed to get this new therapeutic principle on a more efficient way in order to use them in the therapeutic treatment of patients with certain cancer and infectious diseases.
Insights
Human monoclonal antibodies show promise for treating cancer and infectious diseases. Recent advancements address previous experimental challenges, paving the way for more effective therapeutic applications.
Area of Science:
- Immunotechnology
- Biopharmaceutical Development
- Molecular Medicine
Context:
- Review of human monoclonal antibody (mAb) development.
- Exploration of classical cellular fusion, Epstein-Barr virus (EBV) mediated B-lymphocyte transformation, and genetic engineering for chimeric mAbs.
- Discussion of historical clinical and experimental limitations in mAb-based therapies.
Purpose:
- To provide a comprehensive overview of the current state of human monoclonal antibody development.
- To analyze the methodologies employed in generating mAbs, including traditional and modern techniques.
- To highlight recent progress in overcoming obstacles for therapeutic mAb applications.
Summary:
- Details the evolution of human monoclonal antibody production, from cellular fusion to advanced genetic engineering.
- Addresses the historical gap between the therapeutic potential and clinical success of mAbs in oncology and infectious diseases.
- Highlights recent innovations aimed at improving the efficiency and efficacy of monoclonal antibody therapies.
Impact:
- Identifies key challenges and recent breakthroughs in monoclonal antibody research and development.
- Suggests a renewed potential for monoclonal antibodies as effective treatments for specific cancers and infectious diseases.
- Emphasizes the ongoing efforts to translate promising mAb technology into clinical practice for patient benefit.